HDAC9 and cancer: Epigenetic drugs that interfere with heterochromatin formation such as DNMT inhibitors and HDAC inhibitors are used in cancer treatment (Castillo-Aguilera et al., 2017; Pechalrieu et al., 2017; Roberti et al., 2019).